Patient presents with a diagnosis of Hepatitis C Antibody Positive, confirmed by a positive HCV antibody test.  This indicates prior exposure to the Hepatitis C virus.  Further testing, specifically Hepatitis C RNA PCR, is required to determine active versus resolved infection.  Patient history includes (relevant risk factors such as intravenous drug use, blood transfusion before 1992, long-term hemodialysis, occupational exposure to blood, birth to an HCV-positive mother, etc. or negative risk factors).  Physical examination reveals (document relevant findings such as jaundice, hepatomegaly, splenomegaly, ascites, or normal findings).  Current medications, allergies, and relevant social history documented.  Patient counseling regarding the significance of the positive HCV antibody, the need for further HCV RNA testing, transmission precautions, and avoidance of alcohol and hepatotoxic medications provided.  Liver function tests (LFTs), including ALT, AST, alkaline phosphatase, and bilirubin, ordered.  Fibrosis assessment via transient elastography or FibroSure will be considered pending HCV RNA results.  Patient education materials on Hepatitis C provided, and follow-up appointment scheduled to review HCV RNA results and discuss treatment options if indicated.  Diagnosis codes: B18.2 (Chronic viral hepatitis C), Z22.520 (Contact with and suspected exposure to Hepatitis C).  ICD-10-CM codes are subject to change; confirm current coding guidelines.  Potential treatment options discussed included direct-acting antiviral therapy (DAA) regimens if chronic active infection is confirmed.  Potential complications such as cirrhosis, liver failure, and hepatocellular carcinoma were discussed.  Patient demonstrates understanding of the plan of care.